Ware Lab

Tegha, G; Topazian, HM; Kamthunzi, P; Howard, T; Tembo, Z; Mvalo, T; Chome, N; Kumwenda, W; Mkochi, T; Hernandez, A; et al. Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. Gesundheit und Wohlfahrt. Revue suisse d'hygi�ne. 2021; 66.

Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68.

Hood, AM; Strong, H; Nwankwo, C; Johnson, Y; Peugh, J; Mara, CA; Shook, LM; Brinkman, WB; Real, FJ; Klein, MD; et al. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10.

Boucher, AA; Dong, M; Vinks, AA; Marahatta, A; Howard, TA; Ware, RE; Nathan, JD; Abu-El-Haija, M; Luchtman-Jones, L. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. Journal of Clinical Pharmacology. 2021; 61:547-554.

Sadaf, A; Seu, KG; Thaman, E; Fessler, R; Konstantinidis, DG; Bonar, HA; Korpik, J; Ware, RE; McGann, PT; Quinn, CT; et al. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12.

Ware, RE; Dertinger, SD. There's safety in numbers. Blood. 2021; 137:729-731.

Ware, RE; Dertinger, SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology. 2021.

Hernandez, AG; Kiyaga, C; Howard, TA; Ssewanyana, I; Ndeezi, G; Aceng, JR; Ware, RE. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Tropical Medicine and International Health. 2021; 26:23-32.

Cazelles, R; Shukla, RP; Ware, RE; Vinks, AA; Ben-Yoav, H. Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9.

Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT. AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine. 2020; 18.

Ambrose, EE; Smart, LR; Charles, M; Hernandez, AG; Latham, T; Hokororo, A; Beyanga, M; Howard, TA; Kamugisha, E; McElhinney, KE; et al. Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization. 2020; 98:859-868.

George, A; Dinu, B; Estrada, N; Minard, CG; Hurwitz, R; Mahoney, DH; Yates, AM; Vaughan, M; Carmouche, A; Airewele, G; et al. Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology. 2020; 95:E242-E244.

Ware, RE; Marahatta, A; Ware, JL; McElhinney, K; Dong, M; Vinks, AA. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). Journal of Pediatrics. 2020; 222:236-239.

Macharia, AW; Mochamah, G; Uyoga, S; Ndila, CM; Nyutu, G; Tendwa, M; Nyatichi, E; Makale, J; Ware, RE; Williams, TN. β-Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular genetics & genomic medicine. 2020; 8.

Jr, TB L; Lloyd-Puryear, MA; Ohene-Frempong, K; Ware, RE; Padilla, CD; Ambrose, EE; Barkat, A; Ghazal, H; Kiyaga, C; Mvalo, T; et al. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics. 2020; 11:253-268.

John, CC; Opoka, RO; Latham, TS; Hume, HA; Nabaggala, C; Kasirye, P; Ndugwa, CM; Lane, A; Ware, RE. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine. 2020; 382:2524-2533.

Power-Hays, A; Ware, RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology. 2020; 27:172-180.

Hood, AM; McTate, EA; Joffe, NE; Crosby, LE. Sickle Cell Disease. Clinical Handbook of Psychological Consultation in Pediatric Medical Settings. 2020.

Carman, AS; Sautter, C; Anyanwu, JN; Ssemata, AS; Opoka, RO; Ware, RE; Rujumba, J; John, CC. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer. 2020; 67.

Datta, D; Namazzi, R; Conroy, AL; Cusick, SE; Hume, HA; Tagoola, A; Ware, RE; Opoka, RO; John, CC. Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials. 2019; 20.

Boucher, AA; Dong, M; Marahatta, A; Hausfeld, A; Howard, TA; Nathan, JD; Vinks, AA; McGann, PT; Ware, RE; Luchtman-Jones, L. Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption. Blood. 2019; 134:4893-4893.

Smart, LR; Ambrose, EE; Charles, M; Hernandez, AG; Latham, TS; Hokororo, A; Beyanga, M; Kamugisha, E; Tebuka, E; Howard, TA; et al. Genetic Analysis in the Tanzania Sickle Surveillance Study (TS3): Modifiers of Sickle Cell Disease and Identification of Hemoglobin Variants. Blood. 2019; 134:988-988.

Henrici, RC; Sautter, C; Opoka, R; Namazzi, R; Park, GS; John, D; Conroy, AL; Ware, RE; John, CC. Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2. Blood. 2019; 134:2283-2283.

George, A; Dinu, B; Estrada, N; Minard, C; Hurwitz, RL; Mahoney, D; Yates, AM; Vaughan, M; Carmouche, A; Airewele, G; et al. Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle Cell Anemia. Blood. 2019; 134:2267-2267.

Ware, RE; Brown, C; de Montalembert, M; Tonda, M; Tong, B; Hoppe, C; Lehrer-Graiwer, J; Abboud, MR. Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood. 2019; 134:1003-1003.

Ware, RE; Odame, I. Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings. Pediatrics. 2019; 144.

Vichinsky, E; Hoppe, CC; Ataga, KI; Ware, RE; Nduba, V; El-Beshlawy, A; Hassab, H; Achebe, MM; Alkindi, S; Brown, RC; et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine. 2019; 381:509-519.

Ware, RE; McGann, PT; Quinn, CT. Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatric Blood and Cancer. 2019; 66.

McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology. 2019; 94:871-879.

Kiyaga, C; Hernandez, AG; Ssewanyana, I; Schaefer, BA; McElhinney, KE; Ndeezi, G; Howard, TA; Ndugwa, CM; Ware, RE; Aceng, JR. Sickle cell screening in Uganda: High burden, human immunodeficiency virus comorbidity, and genetic modifiers. Pediatric Blood and Cancer. 2019; 66.

Yates, AM; Joshi, VM; Aygun, B; Moen, J; Smeltzer, MP; Govindaswamy, D; Dowdy, J; Cotton, A; Kang, G; Ware, RE; et al. Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. Pediatric Blood and Cancer. 2019; 66.

Grace, RF; Ware, RE. Pediatric Hematology. Hematology/Oncology Clinics of North America. 2019; 33:xiii-xiv.

Vichinsky, E; Hoppe, CC; Ataga, KI; Ware, RE; Nduba, V; El Beshlawy, A; Hassab, H; Achebe, MM; Al-Kindi, S; Brown, C; et al. S147 RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE. HemaSphere. 2019; 3:25-26.

Grace, RF; Ware, RE. Pediatric Hematology. Hematology/Oncology Clinics of North America. 2019; 33.

Ware, RE; Thornburg, CD. Your tired, your poor, your huddled masses. Blood. 2019; 133:2010-2011.

Santos, B; Bernardino, L; Luis, J; da Fonseca, R; Nassesa, L; Andre, DA D O; Cuhna, L; Bengui, AF; de Oliveira, V; Tshilolo, L; et al. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine. 2019; 380:121-131.

Crosby, LE; Walton, A; Shook, LM; Ware, RE; Treadwell, M; Saving, KL; Britto, M; Peugh, J; McTate, E; Oyeku, S; et al. Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology. 2019; 41:56-63.

Kiyaga, C; Hernandez, AG; Ssewanyana, I; McElhinney, KE; Ndeezi, G; Howard, TA; Ndugwa, CM; Ware, RE; Aceng, JR. Building a sickle cell disease screening program in the Republic of Uganda: the Uganda Sickle Surveillance Study (US3) with 3 years of follow-up screening results. Blood Advances. 2018; 2:4-7.

Parker, CJ; Ware, RE. Paroxysmal nocturnal hemoglobinuria. Wintrobe's Clinical Hematology: Fourteenth Edition. 2018.

Shook, LM; Ware, RE. Sickle cell screening in Europe: the time has come. British Journal of Haematology. 2018; 183:534-535.

McGann, PT; Williams, AM; Ellis, G; McElhinney, KE; Romano, L; Woodall, J; Howard, TA; Tegha, G; Krysiak, R; Lark, RM; et al. Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances. 2018; 2:3035-3044.

Rotz, SJ; Ware, RE; Kumar, A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer. 2018; 65.

McGann, PT; Williams, TN; Olupot-Olupot, P; Tomlinson, GA; Lane, A; Reis da Fonseca, JL; Kitenge, R; Mochamah, G; Wabwire, H; Stuber, S; et al. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. American Journal of Hematology. 2018; 93:537-545.

Shook, LM; Ware, RE. Effective screening leads to better outcomes in sickle cell disease. Archives of Disease in Childhood. 2018; 103:628-630.

Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. British Journal of Clinical Pharmacology. 2018; 84:1410-1412.

Thornburg, CD; Ware, RE. Children with sickle cell disease migrating to the United States from sub-Saharan Africa. Pediatric Blood and Cancer. 2018; 65.

Ware, RE; Niss, O. Treatment of Autoimmune Hemolytic Anemia. Immune Hematology. 2018.

Smart, LR; Hernandez, AG; Ware, RE. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology. 2018; 55:102-112.

Rankine-Mullings, AE; Morrison-Levy, N; Soares, D; Aldred, K; King, L; Ali, S; Knight-Madden, JM; Wisdom-Phipps, M; Adams, RJ; Ware, RE; et al. Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. British Journal of Haematology. 2018; 181:242-251.

Smart, LR; Ambrose, EE; Raphael, KC; Hokororo, A; Kamugisha, E; Tyburski, EA; Lam, WA; Ware, RE; McGann, PT. Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study. Annals of Hematology. 2018; 97:239-246.

Opoka, RO; Ndugwa, CM; Latham, TS; Lane, A; Hume, HA; Kasirye, P; Hodges, JS; Ware, RE; John, CC. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017; 130:2585-2593.

Ambrose, EE; Smart, LR; Hokororo, A; Charles, M; Beyanga, M; Hernandez, AG; Howard, TA; Ware, RE. Prevalence and mapping of sickle cell disease in northwestern Tanzania. Blood Advances. 2017; 1:26-28.

Namazzi, R; John, CC; Conroy, AL; Datta, D; Ware, R; Hume, H; Opoka, RO. Development of research capacity in sickle cell anemia in Uganda: impact of collaborations. Blood Advances. 2017; 1:11-13.

Opoka, R; Ndugwa, C; Latham, TS; Lane, A; Hume, HA; Kasirye, P; Hodges, JL; Ware, RE; John, CC. Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM): A Randomized Controlled Trial. Blood. 2017; 130:759-759.

Smart, LR; Ambrose, EE; Raphael, KC; Hokororo, A; Tyburski, EA; Lam, WA; Ware, RE; McGann, PT. Simultaneous Point-of-Care Detection of Anemia and Sickle Cell Disease in Tanzania: The RAPID Study. Blood. 2017; 130:762-762.

Estepp, JH; Smeltzer, MP; Kang, G; Li, C; Wang, WC; Abrams, C; Aygun, B; Ware, RE; Nottage, K; Hankins, JS. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology. 2017; 92:1333-1339.

McGann, PT; Nero, AC; Ware, RE. Clinical Features of β-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology. 2017; 1013:1-26.

Alvarez, O; Nottage, K; Simpson, LM; Wood, J; Davis, BR; Fuh, B; Sarnaik, S; Aygun, B; Helton, K; Ware, RE. Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to non-transfused cohorts. American Journal of Hematology. 2017; 92:E637-E639.

Marahatta, A; Ware, RE. Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells, Molecules, and Diseases. 2017; 67:135-142.

Ware, RE. Technological Advances in Sickle Cell Disease. Blood Cells, Molecules, and Diseases. 2017; 67:102-103.

Chou, ST; Flanagan, JM; Vege, S; Luban, NL C; Brown, RC; Ware, RE; Westhoff, CM. Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Advances. 2017; 1:1414-1422.

Rotz, SJ; Palumbo, JS; Ware, RE. Type 2B von Willebrand Disease: An Unusual Cause of Severe Neonatal Thrombocytopenia. Journal of Pediatric Hematology/Oncology. 2017; 39:473-475.

Ware, RE; de Montalembert, M; Tshilolo, L; Abboud, MR. Sickle cell disease. The Lancet. 2017; 390:311-323.

Jeste, ND; Sanchez, LM; Urcuyo, GS; Berges, ME; Luden, JP; Stuber, SE; Latham, TS; Mena, R; Nieves, RM; Ware, RE. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols. 2017; 6.

Bond, M; Hunt, B; Flynn, B; Huhtinen, P; Ware, R; Richards-Kortum, R. Towards a point-of-care strip test to diagnose sickle cell anemia. PLoS ONE. 2017; 12.

Niss, O; Ware, RE. Sickle Cell Disease. Pediatric and Adult Nutrition in Chronic Diseases, Developmental Disabilities, and Hereditary Metabolic Disorders. 2017.

McGann, PT; Hernandez, AG; Ware, RE. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood. 2017; 129:155-161.

Crosby, LE; Ware, RE; Goldstein, A; Walton, A; Joffe, NE; Vogel, C; Britto, MT. Development and evaluation of iManage: A self-management app co-designed by adolescents with sickle cell disease. Pediatric Blood and Cancer. 2017; 64:139-145.

Crosby, LE; Joffe, NE; Peugh, J; Ware, RE; Britto, MT. Pilot of the Chronic Disease Self-Management Program for Adolescents and Young Adults With Sickle Cell Disease. Journal of Adolescent Health. 2017; 60:120-123.